Amarin Corp Plcuk (AMRN) Assets Average (2011 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Assets Average of $658.3 million for Q1 2026, down 1.83% YoY from $670.5 million in Q1 2025, and down 1.06% sequentially from $665.3 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Assets Average (2011 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Assets Average across 16 years of filings, most recently posting $658.3 million for Q1 2026.
- In Q1 2026, Assets Average fell 1.83% year-over-year to $658.3 million; the TTM figure through Mar 2026 stood at $658.3 million (down 1.83% YoY), while the FY2025 annual figure was $678.1 million, down 10.61% from the prior year.
- Assets Average fell to $658.3 million in Q1 2026, from $665.3 million in the prior quarter.
- Over the last five years, Assets Average for AMRN reached as high as $1.0 billion in Q1 2022 and fell as low as $658.3 million in Q1 2026.
- The 5-year median for Assets Average is $810.8 million (2024), against an average of $804.2 million.
- Annual changes were most pronounced in 2022 — Assets Average advanced 4.37% — and 2025, when it retreated 17.31%.
- A 5-year view of Assets Average shows it stood at $897.2 million in 2022, then fell by 6.9% to $835.4 million in 2023, then dropped by 14.05% to $718.0 million in 2024, then fell by 7.34% to $665.3 million in 2025, then decreased by 1.06% to $658.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $658.3 million, $665.3 million, and $665.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 658.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 658.27 Mn |
| Dec 31, 2025 | 665.29 Mn |
| Sep 30, 2025 | 664.97 Mn |
| Jun 30, 2025 | 662.91 Mn |
| Mar 31, 2025 | 670.52 Mn |
| Dec 31, 2024 | 717.98 Mn |
| Sep 30, 2024 | 775.26 Mn |
| Jun 30, 2024 | 794.96 Mn |
| Mar 31, 2024 | 810.85 Mn |
| Dec 31, 2023 | 835.36 Mn |
| Sep 30, 2023 | 849.52 Mn |
| Jun 30, 2023 | 860.10 Mn |
| Mar 31, 2023 | 873.18 Mn |
| Dec 31, 2022 | 897.24 Mn |
| Sep 30, 2022 | 940.77 Mn |
| Jun 30, 2022 | 973.47 Mn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 1.05 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.02 Bn |